AstraZeneca slams Innopharma for Falsodex generic
New Jersey | 23 February 2016

AstraZeneca has sued Innopharma to block its attempt to produce a generic version of breast cancer treatment Falsodex (fulvestrant).

UK-based pharma AstraZeneca filed its complaint on 16 February at the US District Court for the District of New Jersey, holding that Innopharma’s generic plans would infringe its four patents for the drug, which treats breast cancer.

Innopharma filed an Abbreviated New Drug Application with the Food and Drug Administration for its generic fulvestrant treatment, in which it made a Paragraph IV certification that the patents are either unenforceable or not infringed.

“Innopharma has lacked a good faith basis for alleging invalidity of the patents when it filed its Paragraph IV certification,” claimed AstraZeneca in its complaint.

AstraZeneca is seeking declaratory judgements and an order preventing Innopharma’s generic product from being released until after its four patents have expired.

Author: Tammy Facey



More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences
IPPRO ARCHIVES
BACK ISSUES ONLINE
COMPANY INFO
ABOUT US

THE TEAM


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization